Why Weight Loss Plateaus on GLP-1s Happen — and What Your Doctor Can Actually Do About It
I’m an emergency and Family Medicine physician in Chattanooga, Tennessee, and founder of Summit Metabolic Health. I read every patient chart personally. This article reports on a topic patients keep asking about — it is education, not an endorsement.
Online forums are full of posts like it: seven weeks in, one pound lost, appetite creeping back, and a growing question of whether to just stop. These threads pull dozens of replies because the frustration is real — and the uncertainty about what it means is even more real.
Plateaus Are a Known Part of the Process
Weight loss on GLP-1 medications like semaglutide and tirzepatide rarely moves in a straight line. Early weeks often bring noticeable appetite suppression and steady loss, followed by stretches where the scale barely budges. This isn’t a sign of failure — it’s consistent with how these medications work and how the body responds to caloric deficit over time.
Dose Titration Is Often the Missing Piece
Both semaglutide and tirzepatide are dosed on a titration schedule for a reason: the body needs time to adjust, and effectiveness at a given dose can plateau before the next increase. Someone at a starting or mid-range dose may simply not yet be at the level where appetite suppression and metabolic effects are fully engaged. Adjusting dose isn’t something to guess at — it requires a clinician who knows the full titration schedule, your side effect history, and what’s medically appropriate for your next step.
Metabolic Adaptation Is Real — and Expected
As the body loses weight, resting metabolic rate typically decreases somewhat. This is a well-documented physiological response, not unique to GLP-1 therapy. It means that the same intake and activity level that produced loss in month one may produce less loss in month three, even with the medication working exactly as it should. This is precisely why follow-up matters: a physician can distinguish normal metabolic adaptation from a dose or plan that genuinely needs adjustment.
“Appetite Suppression Fading” Doesn’t Always Mean the Drug Stopped Working
A common report is that appetite suppression feels less intense a few weeks after a dose increase. Sometimes this reflects the body adjusting to a new set point. Sometimes it signals it’s time to discuss the next titration step. And sometimes other factors — sleep, stress, medication timing, or injection technique — are at play. Without a conversation with the prescribing clinician, it’s hard to know which explanation applies, and self-adjusting the dose without guidance can increase side effect risk without solving the underlying issue.
Why Quitting Isn’t the Default Answer
Stopping GLP-1 therapy in response to a plateau — without a clinical conversation first — often means giving up right before a dose adjustment or plan change might help. Weight regain after stopping is also well documented in the research. The more useful path when progress stalls is a structured check-in: reviewing labs, discussing titration timing, examining nutrition and activity patterns, and ruling out anything else contributing to a slowdown.
What Physician Follow-Up Actually Looks Like
At Summit, follow-up visits for patients on semaglutide or tirzepatide include reviewing progress against expected patterns, discussing whether titration is on schedule, and adjusting the overall plan as needed. Plateaus are addressed as a clinical question, not a verdict on whether the medication is “working.”
A physician follow-up can clarify whether it’s a titration issue, a metabolic adaptation, or something else entirely. Talk to a physician →